Physician profile
Zsofia Geck
NPI 1568551182
$2,224.09
in general payments reported to CMS, 2019-2025
13 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $210 · 2021: $135 · 2022: $118 · 2023: $92.61 · 2024: $133 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $1,010.00 | 2019 | |
| Ibsa Pharma INC. | $329.79 | 2019-2021 | |
| Abbvie INC. | $303.80 | 2020-2025 | |
| Horizon Therapeutics Plc | $210.23 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $103.69 | 2023-2024 | Unithroid |
| Ascendis Pharma Endocrinology INC | $87.82 | 2023-2025 | Yorvipath |
| Lilly USA, LLC | $56.20 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $27.84 | 2021 | |
| Eisai INC. | $24.67 | 2024 | |
| Amgen INC. | $22.28 | 2020 | |
| Alexion Pharmaceuticals, INC. | $21.08 | 2020 | |
| Shire North American Group INC | $15.35 | 2019 | |
| Radius Health, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zsofia Geck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.